Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Persistent viral infection with viral reservoirs and detection of circulating spike protein
after the initial acute illness is one potential pathogenic mechanism for Long COVID. This
mechanism may be susceptible to antiviral therapy that blocks viral replication, which has
the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy
of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult
population.